Jenburkt Pharmaceuticals Ltd - Company Profile

Q: Who are the current directors of Jenburkt Pharmaceuticals Ltd?

The current directors of Jenburkt Pharmaceuticals Ltd are Ashish Uttam Bhuta, Sumit Ajaybhai Thakkar, Krishnan Subharaman, Hina Ravindra Mehta, Dilip Harkishandas Bhuta, Pankaj Arun Dantwala, Ashish Rasiklal Shah.

It is a pharma public limited company based in Mumbai, Maharashtra, India, established in 1985.

1985 Mumbai, Maharashtra, India Active

Last Updated: December 22, 2025

Access Report

About Jenburkt Pharmaceuticals Ltd

Jenburkt Pharmaceuticals Ltd, a active public limited company, was established on 10 June 1985 in Mumbai, Maharashtra, India. Engaging in drug formulation & development within the manufacturing sector, it holds CIN: L24230MH1985PLC036541. Registered under ROC Roc Mumbai. it is listed on BSE: 524731. It has an authorized capital of ₹10.00 Cr and a paid-up capital of ₹4.41 Cr.

Formerly known as Jen Burkt Pharmaceuticals Private Limited. It upholds a compliant status. In 2024, it reported revenue of ₹146.63 Cr and a net worth of ₹144.94 Cr. Employing 765 professional, Its leadership includes Ashish Uttam Bhuta (Managing Director), Sumit Ajaybhai Thakkar (Director), Krishnan Subharaman (Director). Past directors included Ashish Uttam Bhuta, Devangi Sanjeev Shah, Krishnan Subharaman. It holds ₹2.03 Cr open charges and ₹16.17 Cr settled loans. Its latest AGM occurred on 18 July 2025, with the balance sheet filed on 31 March 2025. It is based at Nirmala Apts 93 Jay Prakash Rd Andheri W, Mumbai, Maharashtra, 400058.

Company Details

CIN/LLPIN
L24230MH1985PLC036541
Registration Number
036541
Incorporation Date
10 June 1985
Authorized Capital
₹10.00 Cr
Paid-Up Capital
₹4.41 Cr
ROC Code
Roc Mumbai
Listing Status
Listed (BSE: 524731)
Company Status
Active

Key Metrics

Authorised Capital ₹ 10.00 Cr as on 22-12-2025
Paid Up Capital ₹ 4.41 Cr as on 22-12-2025
Company Age 40 Year, 9 Months
Last Filing with ROC 31 Mar 2025
Open Charges ₹ 2.03 Cr as on 22-12-2025
Satisfied Charges ₹ 16.17 Cr as on 22-12-2025
Revenue Growth **** 3.36% (FY 2024)
Profit Growth **** 5.57% (FY 2024)
Ebitda **** 9.06% (FY 2024)
Net Worth 18.43% (FY 2024)
Total Assets **** 16.42% (FY 2024)

Comprehensive Company Insights

Explore comprehensive insights into Jenburkt Pharmaceuticals Ltd — covering financial performance, compliance records, Competitor, shareholding patterns, directors, key metrics, and litigation history. Unlock to see detailed insights and stay informed.

Access Report

Who are the key members and board of directors at Jenburkt Pharmaceuticals Ltd?

Current Directors

Name	Designation	Appointment Date	Status
Ashish Uttam Bhuta	Managing Director	02 Jun 2007	Current
Sumit Ajaybhai Thakkar	Director	26 Jul 2023	Current
Krishnan Subharaman	Director	28 May 2024	Current
Hina Ravindra Mehta	Director	28 Mar 2020	Current
Pankaj Arun Dantwala	Director	28 May 2024	Current
Ashish Rasiklal Shah	Nodal Officer	04 Sep 2019	Current

Past Directors

Name	Designation	Cessation	Status
Pramod Abcsdd	Whole-Time Director	16 Jul 2013	Past
Pramod Abcsdd	Additional Director	05 May 2015	Past
Pramod Abcsdd	Additional Director	29 Jul 2024	Past
Pramod Abcsdd	Additional Director	01 Sep 2020	Past
Pramod Abcsdd	Director	23 Jul 2018	Past
Pramod Abcsdd	Managing Director	13 Jun 2013	Past

Discover detailed profiles of directors and KMP - Unlock leadership insights today!

Financial Performance of Jenburkt Pharmaceuticals.

Jenburkt Pharmaceuticals Ltd, for the financial year ended 2024, experienced modest growth in revenue, with a 3.36% increase. The company also saw a slight improvement in profitability, with a 5.57% increase in profit. The company's net worth Soared by an impressive increase of 18.43%.

Date	Amount	Transaction Name	Valuation	Lead Investors	Investors
Jul, 2021	Amount	Post-IPO - Grab	Valuation	investors	Emtek
Feb, 2021	Amount	Post-IPO - Grab	Valuation	investors	Signite Partners
Jan, 2021	Amount	Post-IPO - Grab	Valuation	investors	Hana Financial Group , GGV Capital
Feb, 2021	Amount	Post-IPO - Grab	Valuation	investors	Signite Partners

Upgrade Required

Full access to Financial is available only for users with an active Premium plan.

Key Matrics
Balance Sheet
Profit and Loss
Cash Flow
Ratios

Metrics

(FY 2023)

YOY Growth

(FY 2022)

(FY 2021)

(FY 2020)

(FY 2019)

Total Revenue

********

3.36%

*******

Revenue from Operations

*******

3.82%

*******

Total Assets

*******

16.42%

*******

Profit or Loss

*******

5.57%

*******

Net Worth

*******

18.43%

*******

EBITDA

*******

9.06%

*******

Discover detailed financial data and - Unlock financial today!

What is the Ownership and Shareholding Structure of Jenburkt Pharmaceuticals?

In 2023, Jenburkt Pharmaceuticals had a promoter holding of 47.56% and a public holding of 52.44%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.

Shareholding Pattern (FY 2024)

Promoters: 92.83%
Public: 4.10%
Others: 3.07%

Shareholding Pattern over the Year

	FY (2024)	FY (2023)	FY (2022)	FY (2021)	FY (2020)
Promoters	92.83	94.62	94.55	94.55	94.55
Public	4.10	3.89	3.95	3.96	3.98
Others	3.07	1.49	1.50	1.49	1.47

Upgrade Required

Full access to Ownership and Shareholding Structure is available only for users with an active Premium plan.

Reveal ownership structures and financial performance - Get instant access now!

Charges (Loans)

Open Charges

₹20,300,000.00

Satisfied Charges

₹161,734,000.00

Charges Breakdown by Lending Institutions

Others : 2.03 Cr

Latest Charge Details

Date	Lender	Amount	Status
21 Nov 2022	Others	₹2.00 Cr	Open
21 Nov 2022	Others	₹0.20 M	Open
21 Nov 2022	Others	₹0.10 M	Open
02 Dec 2022	Others	₹3.00 Cr	Satisfied
21 Oct 2022	Others	₹0.15 M	Satisfied

Explore comprehensive loan charge details -

How Many Employees Work at Jenburkt Pharmaceuticals?

Jenburkt Pharmaceuticals has a workforce of 765 employees as of Apr 10, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.

Employee Date	Number of Employees
2020	78,000
2021	80,500
2022	83,200
2023	86,000
2024	89,500
2025	92,000

Upgrade Required

Full access to People is available only for users with an active Premium plan.

Deals i

Gain comprehensive insights into the Deals and Valuation data of Jenburkt Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Jenburkt Pharmaceuticals's trajectory.

Rating

Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.

Alerts

Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.

Explore deal ratings and alerts - Get instant access now!

Latest Updates, News, and FAQs on Jenburkt Pharmaceuticals

Recent Activity within the Organization

Charges

A charge registered on 28 Aug 2019 via Charge ID 100289026 with Others was fully satisfied on 29 Oct 2025. was recorded as a recent event.
29 Oct 2025
Annual General Meeting

The activity Jenburkt Pharmaceuticals Ltd last Annual general meeting of members was held on 18 Jul 2025 as per latest MCA records. was completed.
18 Jul 2025
Balance Sheet

The activity Jenburkt Pharmaceuticals Ltd has filed its annual Financial statements for the year ended 31 Mar 2025 with Roc Mumbai. was completed.
31 Mar 2025
Charges

The activity A charge registered on 21 Oct 2022 via Charge ID 100627860 with Others was fully satisfied on 22 Jan 2025. was completed.
22 Jan 2025
Director Appointment

Progress on Krishnan Subharaman was appointed as a Director was appointed as a Director on 28 May 2024 & has been associated with this company since 1 year 10 months . was documented.
28 May 2024
Director Appointment

Progress on Pankaj Arun Dantwala was appointed as a Director was appointed as a Director on 28 May 2024 & has been associated with this company since 1 year 10 months . was documented.
28 May 2024

Explore recent activity and updates - View Recent Activity